Drug intelligence / Profile preview

WS 1070

Development stage: Unknown
Lead developer: Schwabe
Administration: Oral

Overview

WS 1070 is a proprietary, standardized herbal extract of *Eleutherococcus senticosus* (Siberian ginseng) developed by Dr. Willmar Schwabe GmbH & Co. KG. Classified as an adaptogen, it is designed to enhance the body's non-specific resistance to various physical and mental stressors. The extract is primarily indicated for the treatment of symptoms associated with asthenia, such as fatigue, weakness, and decreased concentration capacity. Its mechanism of action involves the modulation of the hypothalamic-pituitary-adrenal (HPA) axis and the neuroendocrine system to support resilience and recovery from stress. WS 1070 has been evaluated in Phase IV clinical trials, including studies investigating its synergistic effects when combined with structured stress management programs.

Other names: Siberian ginseng extractEleutherococcus senticosus extract

Beyond the preview

Go deeper on WS 1070.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WS 1070.

Explore the full profile